Genta initiates first clinical trial for bone disease
The first cohort of six normal volunteers has been treated with single doses of G4544 without experiencing significant side effects. G4544 is a new tablet formulation that enables
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta (quizartinib), an oral type II FLT3 inhibitor, in China.